0001209191-15-061951.txt : 20150721
0001209191-15-061951.hdr.sgml : 20150721
20150721201104
ACCESSION NUMBER: 0001209191-15-061951
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150717
FILED AS OF DATE: 20150721
DATE AS OF CHANGE: 20150721
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD.
CITY: NEWARK
STATE: CA
ZIP: 94560
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ruegg Curtis
CENTRAL INDEX KEY: 0001597578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 15998790
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BOULEVARD
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-07-17
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001597578
Ruegg Curtis
C/O REVANCE THERAPEUTICS, INC.
7555 GATEWAY BOULEVARD
NEWARK
CA
94560
0
1
0
0
EVP, Technical Operations
Common Stock
2015-07-17
4
M
0
1836
6.60
A
19863
D
Common Stock
2015-07-17
4
M
0
1164
8.70
A
21027
D
Common Stock
2015-07-17
4
S
0
3000
31.03
D
18027
D
Stock Option (Right to Buy)
6.60
2015-07-17
4
M
0
1836
0.00
D
2016-12-11
Common Stock
1836
0
D
Stock Option (Right to Buy)
8.70
2015-07-17
4
M
0
1164
0.00
D
2023-05-26
Common Stock
1164
58836
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The Option is fully vested as of September 29, 2010.
The shares subject to this Option vest in 48 equal monthly installments over 4 years following May 27, 2013.
/s/ Gordon Ho, Attorney-in-fact
2015-07-21